Ultragenyx's Setrusumab Failure Tests Profitability Path

Ultragenyx Pharmaceutical's setrusumab failed a Phase 3 trial for osteogenesis imperfecta in late December, according to a Seeking Alpha analyst. The setback hit the company's pipeline at a critical moment.

The analyst said setrusumab was supposed to be Ultragenyx's next major commercial product. The rare disease drug developer had pinned hopes on the asset to expand its revenue base beyond its approved products. With the failure, the company now faces a steeper climb to profitability.

Ultragenyx has other programs in development, including gene therapies and enzyme replacement therapies. The loss of a late-stage asset narrows the path to near-term revenue growth. The analyst's financial model for the company depends on successful data from other trials, which are still in earlier stages.

Profitability is the real test, the analyst wrote. Ultragenyx has spent heavily on research and development, and its operating expenses have outpaced revenue. Without a new commercial launch in the near future, the company may need to cut costs or raise capital to extend its runway.

Shares fell after the announcement, reflecting the market's reassessment of the company's prospects. The analyst said the stock price had already priced in some risk but the full impact of the failure may take time to play out.

What to watch next: Ultragenyx plans to present data from its ongoing trials later this year. The analyst highlighted the company's cash position, as reported in its latest filing, which gives it enough runway to fund operations through the next several data readouts.

The analyst concluded that the company's future depends on executing on its remaining pipeline and achieving profitability without a major new product in the near term.